NASDAQ:MRUS - Nasdaq - NL0011606264 - Common Stock - Currency: USD
47.37
-0.26 (-0.55%)
The current stock price of MRUS is 47.37 USD. In the past month the price increased by 15.23%. In the past year, price decreased by -0.17%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 172 full-time employees. The company went IPO on 2016-05-19. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The firm operates in the Netherlands and United States.
MERUS NV
Uppsalalaan 17, 3rd & 4th floor
Utrecht UTRECHT 3584 NL
CEO: Sven A. Lundberg
Employees: 201
Company Website: https://merus.nl/
Investor Relations: https://ir.merus.nl/
Phone: 31850162500
The current stock price of MRUS is 47.37 USD. The price decreased by -0.55% in the last trading session.
The exchange symbol of MERUS NV is MRUS and it is listed on the Nasdaq exchange.
MRUS stock is listed on the Nasdaq exchange.
23 analysts have analysed MRUS and the average price target is 88.8 USD. This implies a price increase of 87.46% is expected in the next year compared to the current price of 47.37. Check the MERUS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MERUS NV (MRUS) has a market capitalization of 3.24B USD. This makes MRUS a Mid Cap stock.
MERUS NV (MRUS) currently has 201 employees.
MERUS NV (MRUS) has a support level at 42.51 and a resistance level at 47.38. Check the full technical report for a detailed analysis of MRUS support and resistance levels.
The Revenue of MERUS NV (MRUS) is expected to decline by -21.2% in the next year. Check the estimates tab for more information on the MRUS EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MRUS does not pay a dividend.
MERUS NV (MRUS) will report earnings on 2025-03-04, after the market close.
MERUS NV (MRUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.9).
The outstanding short interest for MERUS NV (MRUS) is 11.56% of its float. Check the ownership tab for more information on the MRUS short interest.
ChartMill assigns a technical rating of 6 / 10 to MRUS. When comparing the yearly performance of all stocks, MRUS turns out to be only a medium performer in the overall market: it outperformed 53.23% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to MRUS. MRUS has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months MRUS reported a non-GAAP Earnings per Share(EPS) of -3.9. The EPS decreased by -3.72% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -28.95% | ||
ROE | -34.77% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 88% to MRUS. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of -27.78% and a revenue growth -21.2% for MRUS